Multiple US consumers file lawsuits alleging that GLP-1 medicines including Ozempic and Wegovy, and Eli Lilly’s Zepbound, are linked to a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION). NAION can cause sudden vision loss, often in one eye, and the complaints describe vision problems that they say began after taking the drugs.
The reports describe dozens of filed cases and characterize them as allegations rather than proof. NAION is the focus because it is associated with what some claims describe as an “eye stroke.” Medical studies and regulatory reviews described across coverage remain mixed, with no settled determination that GLP-1 drugs cause NAION. The key point highlighted is that the lawsuits proceed on claims of harm and warning failures, while ongoing evidence has not established causation.
Novo Nordisk and Eli Lilly dispute the allegations. Novo Nordisk says it takes reports of adverse events seriously but considers the lawsuits without merit, while Eli Lilly similarly denies links between its medicines and NAION, according to the cited reporting.
